Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Immunovia AB ( (SE:IMMNOV) ) has issued an announcement.
Immunovia has published a model development study in the journal Cancers, validating its technology for early detection of pancreatic cancer. The study, which uses machine learning to identify a five-marker panel with 85% sensitivity and 98% specificity, supports the clinical viability of Immunovia’s PancreaSure test, set to launch in September, marking a significant milestone in cancer care.
More about Immunovia AB
Immunovia AB is a diagnostic company dedicated to improving survival rates for pancreatic cancer patients through early detection. The company focuses on developing and commercializing simple tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to make these tests accessible to high-risk individuals.
YTD Price Performance: -11.17%
Average Trading Volume: 3,922,019
Current Market Cap: SEK148.6M
Find detailed analytics on IMMNOV stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue